Prime Medicine, Inc. Common Stock (PRME) Stock
Key stats
- Market cap
- $779.92M
- Price / Earnings ratio
- -3.8x
- EPS (TTM)
- -$1.08
- Volume
- Loading
- 52-week high
- $5.91
- 52-week low
- $2.67
Source: third-party data provider, as of November 13, 2026
Compare with PRME
Recent news

Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?
Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?
PRME

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
PRME

Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units
Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units
PRME

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
PRME
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 52.33
- MACD 12/26/9
- 0.22
- EMA 9 of MACD
- 0.28
- MACD histogram
- -0.06
- SMA 50
- $3.68
- Price above SMA 50
- EMA 50
- $3.86
- Price above EMA 50
- SMA 200
- $3.50
- Price above SMA 200
- EMA 200
- $3.62
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?
Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?
PRME

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
PRME

Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units
Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units
PRME

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
PRME

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
PRME

Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
PRME

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
PRME

Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
PRME

PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug
PRME

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
PRME
News tone: automated (AI) classification of the article's content, not a price prediction.
About Prime Medicine, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Allan Reine M.D. | CEO & Director | 1975 |
| Mr. Jeffrey D. Marrazzo M.B.A., M.P.A. | Executive Chair | 1979 |
| Ms. Svetlana Makhni | Chief Financial Officer | 1984 |
| Dr. Ann L. Lee Ph.D. | Chief Technical Officer | 1962 |
| Dr. Andrew Anzalone M.D., Ph.D. | Co-Founder & Head of Platform | 1987 |
| Dr. David R. Liu Ph.D. | Co-Founder & Member of Scientific Advisory Board | — |
| Mr. Ryan E. Brown J.D. | Chief Legal Officer | 1979 |
| Ms. Niamh Alix | Chief Human Resources Officer | — |
| Mr. Mohammed Asmal M.D., Ph.D. | Chief Medical Officer | — |
| Dr. Matthew J. Hawryluk M.B.A., Ph.D. | Chief Business Officer | 1979 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 52.33
- MACD 12/26/9
- 0.22
- EMA 9 of MACD
- 0.28
- MACD histogram
- -0.06
- SMA 50
- $3.68
- Price above SMA 50
- EMA 50
- $3.86
- Price above EMA 50
- SMA 200
- $3.50
- Price above SMA 200
- EMA 200
- $3.62
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $7.00
- Average
- $8.00
- High
- $9.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | +22.4 | -18.6 | +12.6 | |||||||||
| 2023 | +0.2 | -6.9 | -24.7 | +14.8 | -2.1 | -0.7 | +3.9 | -10.8 | -25.4 | -25.7 | +13.1 | +9.9 |
| 2024 | -27.5 | +28.6 | -19.9 | -27.2 | +23.0 | -21.5 | +2.4 | -17.5 | +0.3 | +12.5 | -18.4 | -15.4 |
| 2025 | -6.4 | -4.9 | -11.2 | -3.4 | -32.2 | +107.6 | +37.0 | -19.8 | +77.6 | -11.6 | -16.2 | -0.9 |
| 2026 | +7.9 | +21.6 | -25.3 | +4.7 | +4.1 | +8.5 | -24.9 | +27.8 | -14.3 | +57.9 | -3.2 |



